# Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function

> **NCT03049540** · PHASE3 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 100 (actual)

## Conditions studied

- Heart Defects, Congenital
- Transposition of Great Vessels With Ventricular Inversion

## Interventions

- **DRUG:** Tadalafil 20 MG
- **DRUG:** Placebo 20 MG

## Key facts

- **NCT ID:** NCT03049540
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-25
- **Primary completion:** 2021-10-28
- **Final completion:** 2021-10-28
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03049540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03049540, "Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03049540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*